The ASAP1 Knockout HT29 Polyclonal Cells are a heterogeneous population of HT29 human colorectal adenocarcinoma cells engineered via CRISPR/Cas9-mediated disruption of the ASAP1 gene. This polyclonal knockout cell product provides a physiologically relevant loss-of-function model for studying ASAP1-dependent signaling and cellular behaviors. The pooled knockout format captures diverse genetic modifications at the target locus, enabling robust analysis of gene function without the clonal selection bias of monoclonal lines.
The parental HT29 cell line is a well-characterized, microsatellite-stable (MSS) model of colorectal adenocarcinoma, harboring an inactivating mutation in the tumor suppressor APC. These epithelial cells retain a moderate differentiation phenotype and are widely used in studies of intestinal barrier function, tumor progression, and drug response. The APC-mutant background provides a relevant oncogenic context for dissecting pathways that drive colorectal cancer metastasis.
ASAP1 encodes a multi-domain ARF GTPase-activating protein (GAP) that serves as a critical node at the interface between membrane traffic and actin cytoskeleton remodeling. The protein catalyzes GTP hydrolysis on Arf1, Arf5, and Arf6, a reaction that regulates endosomal recycling, focal adhesion dynamics, and cell protrusions. ASAP1 is activated downstream of EGFR, PDGFR, and integrin receptors through Src family kinase-mediated phosphorylation, and it physically interacts with FAK (PTK2), Src, cortactin, paxillin, and phosphatidylinositol 4,5-bisphosphate (PtdIns(4,5)P2). At focal adhesions, ASAP1 forms functional complexes with FAK and Src to coordinate the disassembly of vinculin-, talin-, and paxillin-containing adhesion structures, thereby facilitating turnover of cell?Cmatrix contacts and promoting rapid cytoskeletal remodeling during migration.
In the colorectal cancer context, elevated ASAP1 expression correlates with enhanced invasive and metastatic potential. Disruption of ASAP1 in APC-mutant HT29 cells provides a powerful system to interrogate how ARF GAP activity contributes to focal adhesion turnover, integrin-mediated signaling, and actin polymerization dynamics in epithelial tumor cells. This model is particularly well suited for examining the interplay between oncogenic Wnt/??-catenin signaling??driven by APC loss??and the ASAP1-dependent membrane trafficking and migration machinery. Furthermore, the MSS status of HT29 cells allows investigation of ASAP1??s role independently of microsatellite instability-associated phenotypes common in other colorectal lines.
Researchers can employ these polyclonal knockout cells in a variety of targeted assays to dissect ASAP1 function. Quantitative Western blotting for ASAP1, FAK, and phospho-FAK enables confirmation of knockout and downstream signaling effects. Immunofluorescence microscopy can visualize focal adhesion morphology and actin organization. Functional migration and invasion studies using Transwell inserts or wound-healing assays provide direct readouts of cell motility. Additionally, co-immunoprecipitation experiments can probe ASAP1??s association with FAK and Src, while ARF GAP activity assays biochemically validate the loss of catalytic function. These tools facilitate drug target discovery for anti-metastatic therapies and detailed mechanistic studies of Arf GTPase signaling in colorectal cancer. For further information, please contact Ascent Research.
